Bohdan Andreiuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Bohdan Andreiuk has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
Adam Gamson
1 shared publicationAmy Cameron
Department of Imaging, Dana-Farber Cancer Institute and Harvard Medical School
1 shared publicationAndrea Protti
Department of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School
1 shared publicationAndrew Whitley
HORIBA Instruments Incorporated
1 shared publication- Andrey S. Klymchenko
Université de Strasbourg, CNRS
1 shared publication Anila Hoskere Ashoka
Univ. de Strasbourg (France)
1 shared publication
Latest Publications
- Open Access
- 23 March 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Lyophilized monoclonal antibody (mAb) encoded mRNA—lipid nanoparticles (LNPs) lead to stable in vivo expression of mAb after room temperature storage
The recent success of mRNA COVID-19 vaccines using lipid nanoparticles (LNPs) underscores the potential of this technology for delivering gene-encoded biologics in humans. Passive immunization by in vivo expression of monoclonal antibodies (mAbs) could provide advantages over traditional vaccines due to its immediate protection and broader applicability. The use of mRNA allows for rapid development and easily scalable production, while in vivo expression of biologics (IVEB) reduces the complexity and cost associated with traditional mAb manufacturing by leveraging the body as a bioreactor. However, the requirement of cold chain storage and transportation remains a critical challenge for the distribution of mRNA-LNP formulations. Lyophilization of the mRNA-LNP formulations to produce dry powder offers a potential solution to this issue. In this study, we have investigated several lyophilization conditions for mRNA-LNP and evaluated their efficacy both in vitro and in vivo . Further physical stability and structure characterization provided insights into the structure-efficacy relationship. We successfully identified the lyophilization condition using 5 mM Tris buffer at pH 8 with 10% sucrose, which retained LNP particle size within an acceptable range, preserved mRNA encapsulation efficiency, and maintained consistent level of in vivo expressed mAbs after being stored at room temperature for a month.
- 23 March 2026
- Published by Springer Nature in AAPS Open
- Vol. 12 (1)
Open AccessLyophilized monoclonal antibody (mAb) encoded mRNA—lipid nanoparticles (LNPs) lead to stable in vivo expression of mAb after room temperature storage
The recent success of mRNA COVID-19 vaccines using lipid nanoparticles (LNPs) underscores the potential of this technology for delivering gene-encoded biologics in humans. Passive immunization by in vivo expression of monoclonal antibodies (mAbs) could provide advantages over traditional vaccines due to its immediate protection and broader applicability. The use of mRNA allows for rapid development and easily scalable production, while in vivo expression of biologics (IVEB) reduces the complexity and cost associated with traditional mAb manufacturing by leveraging the body as a bioreactor. However, the requirement of cold chain storage and transportation remains a critical challenge for the distribution of mRNA-LNP formulations. Lyophilization of the mRNA-LNP formulations to produce dry powder offers a potential solution to this issue. In this study, we have investigated several lyophilization conditions for mRNA-LNP and evaluated their efficacy both in vitro and in vivo . Further physical stability and structure characterization provided insights into the structure-efficacy relationship. We successfully identified the lyophilization condition using 5 mM Tris buffer at pH 8 with 10% sucrose, which retained LNP particle size within an acceptable range, preserved mRNA encapsulation efficiency, and maintained consistent level of in vivo expressed mAbs after being stored at room temperature for a month.
- Open Access
In vivo Imaging using Surface Enhanced Spatially Offset Raman Spectroscopy (SESORS): Balancing Sampling Frequency to Improve Overall Image Acquisition
Background and Rationale: In the field of optical imaging, the ability to image tumors at depth with high selectivity and specificity remains a challenge. Surface enhanced resonance Raman scattering (SERRS) nanoparticles (NPs) can be employed as image contrast agents to specifically target cells in vivo , however, this technique typically requires time-intensive point-by-point acquisition of Raman spectra, thus hindering the real-time image acquisition desired for clinical applications. Moreover, traditional approaches involving Raman spectroscopy are limited in their inability to probe through tissue depths of more than a few millimeters. Here, we combine the use of “spatially offset Raman spectroscopy” (SORS) with that of SERRS in a technique known as “surface enhanced spatially offset resonance Raman spectroscopy” (SESORRS) to image deep-seated tumors in vivo . Additionally, by accounting for the laser spot size, we report an experimental SESORRS approach for detecting both the bulk tumor, subsequent delineation of tumor margins at high speed, and the identification of a deeper secondary region of interest with fewer measurements than are typically applied. Methods: To enhance light collection efficiency, four modifications were made to a previously described custom-built SORS system. Specifically, the following parameters were increased: (i) the numerical aperture (NA) of the lens, from 0.2 to 0.34; (ii) the working distance of the probe, from 9 mm to 40 mm; (iii) the NA of the fiber, from 0.2 to 0.34; and (iv) the fiber diameter, from 100 µm to 400 µm. To calculate the sampling frequency, which refers to the number of data point spectra obtained for each image, we considered the laser spot size of the elliptical beam (6 × 4 mm). Using SERRS contrast agents, we performed in vivo SESORRS imaging on a GL261-Luc mouse model of glioblastoma at four distinct sampling frequencies: par-sampling frequency (12 data points collected), and over-frequency sampling by factors of 2 (35 data points collected), 5 (176 data points collected), and 10 (651 data points collected). Results: In comparison to the previously reported SORS system, the modified SORS instrument showed a 300% improvement in signal-to-noise ratios (SNR). Glioblastomas were imaged in vivo using SESORRS in mice (n = 3) and tumors were confirmed using MRI and histopathology. The results demonstrate the ability to acquire distinct Raman spectra from deep-seated glioblastomas in mice through the skull using a low power density (6.5 mW/mm 2 ) and 30-times shorter integration times than a previous report (0.5 s versus 15 s). The ability to map the whole head of the mouse and determine a specific region of interest using as few as 12 spectra (6 second total acquisition time) is achieved. Subsequent use of a higher sampling frequency demonstrates it is possible to delineate the tumor margins in the region of interest with greater certainty. In addition, SESORRS images indicate the emergence of a secondary tumor region deeper within the brain in agreement with MRI and H&E staining. Conclusion: In comparison to traditional Raman imaging approaches, this approach enables improvements in the rapid detection of deep-seated tumors in vivo through depths of several millimeters due to improvements in SNR, spectral resolution, and depth acquisition. This approach offers an opportunity to navigate larger areas of tissues in shorter time frames than previously reported, identify regions of interest, and then image such area with greater resolution using a higher sampling frequency. Moreover, using a SESORRS approach, we demonstrate that it is possible to detect secondary, deeper-seated lesions through the intact skull.
Open AccessIn vivo Imaging using Surface Enhanced Spatially Offset Raman Spectroscopy (SESORS): Balancing Sampling Frequency to Improve Overall Image Acquisition
Background and Rationale: In the field of optical imaging, the ability to image tumors at depth with high selectivity and specificity remains a challenge. Surface enhanced resonance Raman scattering (SERRS) nanoparticles (NPs) can be employed as image contrast agents to specifically target cells in vivo , however, this technique typically requires time-intensive point-by-point acquisition of Raman spectra, thus hindering the real-time image acquisition desired for clinical applications. Moreover, traditional approaches involving Raman spectroscopy are limited in their inability to probe through tissue depths of more than a few millimeters. Here, we combine the use of “spatially offset Raman spectroscopy” (SORS) with that of SERRS in a technique known as “surface enhanced spatially offset resonance Raman spectroscopy” (SESORRS) to image deep-seated tumors in vivo . Additionally, by accounting for the laser spot size, we report an experimental SESORRS approach for detecting both the bulk tumor, subsequent delineation of tumor margins at high speed, and the identification of a deeper secondary region of interest with fewer measurements than are typically applied. Methods: To enhance light collection efficiency, four modifications were made to a previously described custom-built SORS system. Specifically, the following parameters were increased: (i) the numerical aperture (NA) of the lens, from 0.2 to 0.34; (ii) the working distance of the probe, from 9 mm to 40 mm; (iii) the NA of the fiber, from 0.2 to 0.34; and (iv) the fiber diameter, from 100 µm to 400 µm. To calculate the sampling frequency, which refers to the number of data point spectra obtained for each image, we considered the laser spot size of the elliptical beam (6 × 4 mm). Using SERRS contrast agents, we performed in vivo SESORRS imaging on a GL261-Luc mouse model of glioblastoma at four distinct sampling frequencies: par-sampling frequency (12 data points collected), and over-frequency sampling by factors of 2 (35 data points collected), 5 (176 data points collected), and 10 (651 data points collected). Results: In comparison to the previously reported SORS system, the modified SORS instrument showed a 300% improvement in signal-to-noise ratios (SNR). Glioblastomas were imaged in vivo using SESORRS in mice (n = 3) and tumors were confirmed using MRI and histopathology. The results demonstrate the ability to acquire distinct Raman spectra from deep-seated glioblastomas in mice through the skull using a low power density (6.5 mW/mm 2 ) and 30-times shorter integration times than a previous report (0.5 s versus 15 s). The ability to map the whole head of the mouse and determine a specific region of interest using as few as 12 spectra (6 second total acquisition time) is achieved. Subsequent use of a higher sampling frequency demonstrates it is possible to delineate the tumor margins in the region of interest with greater certainty. In addition, SESORRS images indicate the emergence of a secondary tumor region deeper within the brain in agreement with MRI and H&E staining. Conclusion: In comparison to traditional Raman imaging approaches, this approach enables improvements in the rapid detection of deep-seated tumors in vivo through depths of several millimeters due to improvements in SNR, spectral resolution, and depth acquisition. This approach offers an opportunity to navigate larger areas of tissues in shorter time frames than previously reported, identify regions of interest, and then image such area with greater resolution using a higher sampling frequency. Moreover, using a SESORRS approach, we demonstrate that it is possible to detect secondary, deeper-seated lesions through the intact skull.
- Open Access
- 1 April 2020
- Published by SPIE-Intl Soc Optical Eng
- Vol. 11362, 113620P-23
Near-infrared fluorescent coatings for medical devices (Conference Presentation)
Fluorescent dyes that emit in the near-infrared (NIR) region gained increasing attention in medical imaging and fluorescence guided surgery. [1,2] Optical imaging allows the surgeons to visualize the normal and diseased tissues in real-time.[2] Particularly interesting in this respect is NIR fluorescent coatings on medical devices such as implants, catheters and stents etc., which are extensively used in various treatments and surgical procedures. However, most of the existing coating materials are composed of either indocyanine green (ICG) or other visible/blue light active fluorophores. ICG-based coatings suffer from limited brightness and poor photostability whereas blue/visible light active coatings are not compatible with well-established laparoscopic systems. [3] Here, we introduce new NIR coating material composed of cyanine dye salts and a biocompatible polymer. [4] The dye is encapsulated into the polymer coating with help of bulky counterions, which, according to our studies on polymeric nanoparticles, [5] prevents dye leakage and minimizes self-quenching. A series of dyes based on cyanine 7.5 family were synthesized and tested. In comparison to ICG-based coatings, our new NIR coatings exhibit superior brightness and photostability Moreover, these coating materials showed good adhesion properties and useful to coat medical devices, including metallic fiducials and catheters. Such coated medical devices show high fluorescence brightness and exceptional stability in air and buffer medium for at least 150 days. Moreover, our coatings are biocompatible and thus, appear promising for biomedical use. We have demonstrated the various possible medical applications of the NIR coated devices (fiducials and catheters) in ex-vivo and in-vivo porcine models. Funding: This work was supported by “NICE” grant of SATT Conectus, Alsace. References: [1] A. H. Ashoka, et. al. J Phys Chem Lett, 2019, 10, 2414. [2] S. Hernot et. al. Lancet Oncol, 2019, 20, e354. [3] Y. Choi et. al. Surg Endosc 2011, 25, 2372. [4] European patent application filed. [5] Reisch, et al., Nature Commun., 2014, 5, 4089.
- 1 April 2020
- Published by SPIE-Intl Soc Optical Eng
- Vol. 11362, 113620P-23
Open AccessNear-infrared fluorescent coatings for medical devices (Conference Presentation)
Fluorescent dyes that emit in the near-infrared (NIR) region gained increasing attention in medical imaging and fluorescence guided surgery. [1,2] Optical imaging allows the surgeons to visualize the normal and diseased tissues in real-time.[2] Particularly interesting in this respect is NIR fluorescent coatings on medical devices such as implants, catheters and stents etc., which are extensively used in various treatments and surgical procedures. However, most of the existing coating materials are composed of either indocyanine green (ICG) or other visible/blue light active fluorophores. ICG-based coatings suffer from limited brightness and poor photostability whereas blue/visible light active coatings are not compatible with well-established laparoscopic systems. [3] Here, we introduce new NIR coating material composed of cyanine dye salts and a biocompatible polymer. [4] The dye is encapsulated into the polymer coating with help of bulky counterions, which, according to our studies on polymeric nanoparticles, [5] prevents dye leakage and minimizes self-quenching. A series of dyes based on cyanine 7.5 family were synthesized and tested. In comparison to ICG-based coatings, our new NIR coatings exhibit superior brightness and photostability Moreover, these coating materials showed good adhesion properties and useful to coat medical devices, including metallic fiducials and catheters. Such coated medical devices show high fluorescence brightness and exceptional stability in air and buffer medium for at least 150 days. Moreover, our coatings are biocompatible and thus, appear promising for biomedical use. We have demonstrated the various possible medical applications of the NIR coated devices (fiducials and catheters) in ex-vivo and in-vivo porcine models. Funding: This work was supported by “NICE” grant of SATT Conectus, Alsace. References: [1] A. H. Ashoka, et. al. J Phys Chem Lett, 2019, 10, 2414. [2] S. Hernot et. al. Lancet Oncol, 2019, 20, e354. [3] Y. Choi et. al. Surg Endosc 2011, 25, 2372. [4] European patent application filed. [5] Reisch, et al., Nature Commun., 2014, 5, 4089.